Technology & Software Global On demand · 24-48h

Global Genetic Testing for Cancer Risk Market Strategic Research Report

Name: Global Genetic Testing for Cancer Risk Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Genetic Testing for Cancer Risk Market Strategic Rese…

$3,500 USD

Strategic Research Report

Global Genetic Testing for Cancer Risk Market

$5.74B2025

12.8%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Breast Cancer Risk Genetic Testing, Stomach Cancer Risk Gene Testing, Rectal Cancer Risk Genetic Testing, Others

By Application: Hospital, Clinic, Laboratory

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Myriad Genetics, Inc., Invitae Corporation, Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, CooperSurgical, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Twist Bioscience, Sophia Genetics, Fulgent Genetic, Inc., Medgenome, CENTOGENE, CeGaT, LifeLabs Genetics, Ambry Genetics, BGI, SOFIVA GENOMICS, Yikon Medical

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2025 · forecast to 2032

Length: 153 pages

Market size 2025

$5.74B

Billion USD

Forecast CAGR

12.8%

2025-2032

Forecast 2032

$13.3B

Projected

Régions

Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Genetic Testing for Cancer Risk market size is predicted to grow from US$ 5,738 million in 2025 to US$ 13,100 million in 2032; it is expected to grow at a CAGR of 12.8% from 2026 to 2032.

Cancer risk genetic testing looks for changes in someone"s genes. Genetic changes can cause some cancers. Some cancers can run in families.

The demand for genetic testing for cancer risk has been increasing in recent years due to the growing understanding of the role of genetics in cancer development and the desire for personalized healthcare. Genetic tests can provide valuable information for individuals and healthcare professionals, allowing for early detection, prevention, and personalized treatment strategies.

This report presents a comprehensive overview of the global Genetic Testing for Cancer Risk market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Breast Cancer Risk Genetic Testing
Stomach Cancer Risk Gene Testing
Rectal Cancer Risk Genetic Testing
Others

Segment by Application

Hospital
Clinic
Laboratory

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Genetic Testing for Cancer Risk market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Hospital, Clinic, Laboratory evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Genetic Testing for Cancer Risk Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports

Market size CAGR 12.8%

Regional growth momentum

Market share by segment

Key metrics

Base value

$5.74B

2025

Forecast

$13.3B

2032

CAGR

12.8%

2025–2032

Régions

global

Key companies

Myriad Genetics, Inc.Invitae CorporationIllumina, Inc.Natera, Inc.Laboratory Corporation of America HoldingsF. Hoffmann-La Roche LtdQuest Diagnostics IncorporatedCooperSurgical, Inc.

Segments covered in this report

By Type

Breast Cancer Risk Genetic TestingStomach Cancer Risk Gene TestingRectal Cancer Risk Genetic TestingOthers

By Application

HospitalClinicLaboratory

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Breast Cancer Risk Genetic Testing
3.1.3 Stomach Cancer Risk Gene Testing
3.1.4 Rectal Cancer Risk Genetic Testing
3.1.5 Others
3.1.6 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Hospital
4.1.3 Clinic
4.1.4 Laboratory
4.1.5 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Myriad Genetics, Inc.
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Invitae Corporation
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 Illumina, Inc.
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 Natera, Inc.
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 Laboratory Corporation of America Holdings
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 F. Hoffmann-La Roche Ltd
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 Quest Diagnostics Incorporated
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 CooperSurgical, Inc.
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 Agilent Technologies, Inc.
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Thermo Fisher Scientific, Inc.
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 Twist Bioscience
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)
8.12 Sophia Genetics
8.12.1 Company Overview
8.12.2 Key Products & Segments
8.12.3 Financial Performance (2023–2025)
8.12.4 Business Strategy
8.12.5 SWOT Analysis
8.12.6 Strategic Implications (2026–2032)
8.13 Fulgent Genetic, Inc.
8.13.1 Company Overview
8.13.2 Key Products & Segments
8.13.3 Financial Performance (2023–2025)
8.13.4 Business Strategy
8.13.5 SWOT Analysis
8.13.6 Strategic Implications (2026–2032)
8.14 Medgenome
8.14.1 Company Overview
8.14.2 Key Products & Segments
8.14.3 Financial Performance (2023–2025)
8.14.4 Business Strategy
8.14.5 SWOT Analysis
8.14.6 Strategic Implications (2026–2032)
8.15 CENTOGENE
8.15.1 Company Overview
8.15.2 Key Products & Segments
8.15.3 Financial Performance (2023–2025)
8.15.4 Business Strategy
8.15.5 SWOT Analysis
8.15.6 Strategic Implications (2026–2032)
8.16 CeGaT
8.16.1 Company Overview
8.16.2 Key Products & Segments
8.16.3 Financial Performance (2023–2025)
8.16.4 Business Strategy
8.16.5 SWOT Analysis
8.16.6 Strategic Implications (2026–2032)
8.17 LifeLabs Genetics
8.17.1 Company Overview
8.17.2 Key Products & Segments
8.17.3 Financial Performance (2023–2025)
8.17.4 Business Strategy
8.17.5 SWOT Analysis
8.17.6 Strategic Implications (2026–2032)
8.18 Ambry Genetics
8.18.1 Company Overview
8.18.2 Key Products & Segments
8.18.3 Financial Performance (2023–2025)
8.18.4 Business Strategy
8.18.5 SWOT Analysis
8.18.6 Strategic Implications (2026–2032)
8.19 BGI
8.19.1 Company Overview
8.19.2 Key Products & Segments
8.19.3 Financial Performance (2023–2025)
8.19.4 Business Strategy
8.19.5 SWOT Analysis
8.19.6 Strategic Implications (2026–2032)
8.20 SOFIVA GENOMICS
8.20.1 Company Overview
8.20.2 Key Products & Segments
8.20.3 Financial Performance (2023–2025)
8.20.4 Business Strategy
8.20.5 SWOT Analysis
8.20.6 Strategic Implications (2026–2032)
8.21 Yikon Medical
8.21.1 Company Overview
8.21.2 Key Products & Segments
8.21.3 Financial Performance (2023–2025)
8.21.4 Business Strategy
8.21.5 SWOT Analysis
8.21.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Genetic Testing for Cancer Risk market size?

The global Genetic Testing for Cancer Risk market is estimated at US$ 5.74 billion in 2025 (base year) and is projected to reach US$ 13.1 billion by 2032.

What growth rate is expected for the Genetic Testing for Cancer Risk market through 2032?

The market is expected to grow at a CAGR of 12.8% from 2026 to 2032, expanding from US$ 5.74 billion in 2025 to US$ 13.1 billion in 2032, roughly 2.3 times its base-year value.

How is Genetic Testing for Cancer Risk defined?

Cancer risk genetic testing looks for changes in someone"s genes. Genetic changes can cause some cancers. Some cancers can run in families.

What are the main segments of the Genetic Testing for Cancer Risk market by type?

By type, the market is segmented into Breast Cancer Risk Genetic Testing, Stomach Cancer Risk Gene Testing, Rectal Cancer Risk Genetic Testing and Others.

Which applications drive demand in the Genetic Testing for Cancer Risk market?

Key applications covered include Hospital, Clinic and Laboratory.

Who are the key players in the Genetic Testing for Cancer Risk market?

Key players profiled include Myriad Genetics, Invitae Corporation, Illumina, Natera, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated and CooperSurgical, among 21 companies covered in total.

Which regions and countries are covered for Genetic Testing for Cancer Risk?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

Who should buy the Genetic Testing for Cancer Risk market report?

The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Laboratory, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Genetic Testing for Cancer Risk market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.